Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor - Top-Institutions - MDSpire

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor

  • By

  • Naseema Gangat

  • Kebede H. Begna

  • Aref Al-Kali

  • William Hogan

  • Mark Litzow

  • Animesh Pardanani

  • Ayalew Tefferi

  • January 4, 2023

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Myeloproliferative Neoplasms

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Clinical Trials

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Myeloproliferative Disorders

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Hematology
    • Oncology
    • Clinical Research

  • #5

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Oncology
    • Bone Marrow Transplantation

Original Source(s)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor

  • by Naseema Gangat, Kebede H. Begna, Aref Al-Kali, William Hogan, Mark Litzow, Animesh Pardanani, Ayalew Tefferi

  • January 4, 2023

Related Content

Health-economic evaluation of a novel personalized digital avatar-based anemia management software in hemodialysis patients

CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease

An investigational Cas12a-edited stem cell treatment sharply boosted HbF and largely eliminated vaso-occlusive crises in an early trial

  • April 13, 2026

  • 2 min
Case Study: Two Instances of Idiopathic Plasmacytic Lymphadenopathy, a Subtype of Idiopathic Multicentric Castleman Disease, Accompanied by Xanthelasma Palpebrum from a Canadian Institution